Pheromones are striking species-specific chemosignals that control a wide range of social behaviours in animals (Karlson and Luscher, 1959) . These are otherwise unimportant chemical compounds that range in structure from volatile small molecules
. A noticeable effect here is the variation of hedonic perception across the ovarian cycle that is associated with another putative human pheromone, androstenone (5-α-androst-16en-3α-on), which elicits neutral or unpleasant smell sensations according to the ovulatory and non-ovulatory periods, respectively (Hummel et al 1991; Grammer, 1993) . Similarly, the preferences of women for male faces, voices, masculinity and behavioural displays, and the neuromodulation of the reward system depend on the phases of the ovarian cycle (Dreher et It has also been demonstrated that ovarian hormones can control sexual arousal and that women present a sexual arousal peak around ovulation (Adams et al, 1978; Matteo and Rissman, 1984; Wallen, 1990 ). 4 Therefore, even 50 years after their discovery, the open question remains whether sexual and reproductive behaviour in humans depends on interactions between these sexual pheromones and the hormone status. To investigate this question, we compared the dynamics of facial cutaneous temperature in women during their ovulatory versus non-ovulatory conditions, while they were exposed to androstadienone. Indeed, facial cutaneous temperature is controlled by the ANS, and it might thus represent a These signals were recorded across three experimental phases: adaptation, during which time the women adapted to the experimental set-up while being exposed to the placebo (double-distilled water); stimulation, with the women exposed to androstadienone; and recovery, with the women again exposed to the placebo. In the control experiments, the placebo was instead administered during all three of these phases. Baseline normalisation and trend corrections were then applied to analyse the time-courses of the temperature curves. Figure 1 shows representative high-resolution images of the facial temperature changes induced during placebo exposure and exposure to the pheromone androstadienone in ovulatory and non-ovulatory women under the adaptation (AP), stimulation (SP) and recovery (RP) periods. These temperature modifications showed region-based amplitude variations, within a range of 28 °C to 37 °C. 5 The exposure of the ovulatory and non-ovulatory women to the pheromone produced marked differences in both the spatial patterns ( Fig. 1 ) and time-courses ( Fig.   2 ) of the whole-face temperatures across the experimental phases. For these average group temperatures, during the stimulation and recovery periods the whole-face temperatures increased with the ovulatory women and decreased with the non-ovulatory women (Fig. 2) . Indeed, for androstadienone exposure as recovery period vs. stimulation period, there was a significant continuous increase in the ovulatory women (p <0.001; paired t-test) and a significant continuous decrease in the non-ovulatory women (p <0.05; paired t-test), compared to placebo exposure, where no changes were seen. This group analysis thus highlighted the dramatic influence of the ovulatory condition on the temperature time-course induced by exposure to the pheromone.
When pixel-by-pixel subtraction algorithms were applied to these thermal image series (after movement correction and image re-alignment), the representative highresolution subtraction image series shown in Figure 3 highlighted the temperature differences in specific facial regions across the ovulatory conditions and time-course phases. In particular, with the ovulatory women, androstadienone exposure induced scattered-shaped increases in the temperatures for the nose, forehead, lachrymal gland and peri-oral region. Conversely, androstadienone administration with the nonovulatory women caused scattered decreases in the temperatures in these same regions.
The control (placebo) exposure produced only a generalised cooling of the face temperature, with this placebo trend adjusted for in the following data analysis.
These findings prompted us to further investigate the time-courses in these specific localised facial regions, which correspond to responsive areas for neurophysiological activation described in the literature (Pavlidis, 2002; Shastri, 2009 ). Figure 4 shows the group-averaged temperatures across the full time-courses for the pheromone (and placebo) exposure periods for six specific regions of interest (ROIs): 6 the right and left lachrymal regions and cutaneous projections of the corrugator muscles, and the forehead and the nose. The temperatures across these ROIs showed essentially similar behaviours. In the ovulatory women, exposure to androstadienone initially showed little change from placebo during the exposure (stimulation) period, except for a significant activation peak more specifically for the right lachrymal region and the nose (p <0.05 and p <0.01, respectively). Then upon removal of androstadienone, there were rises in the temperatures across these ROIs for the duration of the recovery period. In contrast, in the non-ovulatory women, exposed to androstadienone, there was an almost immediate cooling down of all of these facial regions (except for the nose) that generally continued through the recovery period. Paired t-tests for phase-to-phase comparisons highlighted the significant differences in the temperature variations across these ROIs, which were not seen under placebo administration or during the adaptation phase ( Table 1 ).
The largest variations here were seen for the nose, the temperature of which appeared to show a significant late activation peak during the recovery phase following androstadienone exposure in both the ovulatory and non-ovulatory women (p <0.001 for both), as also seen for the forehead region with the non-ovulatory women (Fig. 4 ). Figure 5 shows the time variations of the group-averaged autonomic parameters recorded, following baseline normalisation and placebo-trend correction. Here, the palm temperature reproduced the nose and forehead temperature time-courses, thus suggesting a systemic effect of androstadienone on temperature control. Moreover, in the ovulatory women, the palm temperature appeared to be the most responsive parameter to androstadienone administration. Similarly, the galvanic skin response showed a dramatic increase in the ovulatory women during the recovery phase. 7 In particular, the pulse rate also significantly increased with androstadienone exposure under both ovulatory and non-ovulatory conditions (Fig. 4 ). These were seen as higher values with the ovulatory women during the exposure, although during the recovery phase, the pulse rates of the non-ovulatory women increased such that they matched those of the ovulatory women at the end of the observation period (Fig. 4) .
Finally, the breathing rates significantly decreased with androstadienone administration under both the ovulatory and non-ovulatory conditions, with a larger decrease seen during the androstadienone exposure for the non-ovulatory women. Again, during the recovery phase after androstadienone exposure, the breathing rates of the ovulatory and non-ovulatory women reached similar final values, while remaining significantly lower than their control values.
In summary, the androstadienone administration appears to activate different ANS responses according to the physiological, ovulatory versus non-ovulatory, conditions of these women. These ANS responses appear to resemble antagonistic parasympatheticsympathetic-like effects, which might be responsible for the scattered or oscillatory behaviour found on both the spatial and time patterns of these temperature changes.
Thus, both of these systems respond to androstadienone, but to different levels that depend on the physiological status of the woman. Incongruities across these studies can also be ascribed to pheromone solvent and stimulus interactions, or to sexual differences (Wysocki et al, 2009 ). However, these data can be explained by the action of two hormones, as androgens and oestrogens, that separately stimulate antagonistic parasympathetic and sympathetic systems, resulting in synergistic effects on libido and sexual arousal at different levels in both men and women.
Such sexual arousability is related to a natural asymmetric balance of hormones that can induce 'lopsided' sympatho-parasympathetic effects. This asymmetric balance of hormones is the more functional relationship between the two autonomic components, which act agonistically on the parasympathetic and sympathetic centres One aspect of our data shows changes in the rates and time-courses of the autonomic parameters recorded (galvanic skin response, palm temperature, pulse rate, breathing rate). These modifications are in harmony with the physiological status of the women exposed to androstadienone. Furthermore, our results stress that although both of the ANS systems are antagonistically activated by androstadienone, the activation is strongly linked to the physiological hormone status, which results in agonistic effects on sexual and reproductive behaviour.
Here, we have focussed our evaluations on the effects of the physiological conditions of these women during (and after) their exposure to androstadienone by measuring their facial temperatures using high-resolution thermal infrared imaging. This technique demonstrates that exposure to androstadienone elicits different physiological responses that are mediated by activation of the ANS and that appear to result in both sympathetic-like and parasympathetic-like effects that are linked to hormone status.
Androstadienone increased facial temperature in the ovulatory women, priming scattered patterns of temperature variations. Conversely, androstadienone reduced the superficial skin temperature of the face in the non-ovulatory women. This is in agreement with the physiological mechanisms of sexual arousal, which are reinforced when the sympathetic and parasympathetic systems are simultaneously activated to different degrees. In women, opposite hormonal asymmetries would induce opposite 10 sympatho-parasympathetic sexual asymmetries, such that general sensation and arousal are linked to the parasympathetic sexual system, while the local erogenous sensations are linked to the sympathetic system. In summary, the strong-weak balance of these two classes of hormones generates concomitant but asymmetric functioning of the sympatho-parasympathetic systems during sexual arousal (Motofei and Rowland, 2005 ).
This autonomic balance can be elicited with hormones and/or modulated by pheromones, to reach the activation levels of each of the autonomic systems.
Furthermore, the asymmetric functioning of the sympatho-parasympathetic systems is highlighted by comparing these androstadienone effects with respect to the hormone status of the woman, as ovulatory versus non-ovulatory. Here, androstadienone appeared to cause a general thermal increase in the ovulatory women that was amplified in localised regions. These antagonistic effects resulted in regionalised oscillations of the temperatures in specific scattered patterns. Moreover, thermal fluctuations that suggest a double heat-peak response to androstadienone were detectable: an early response over the first few minutes of activation that is in agreement with previous studies (Jacob and McClintock, 2000) , and a delayed response that is compatible with middle-to-late responses (Grosser et al., 2000; Bensafi et al., 2003) .
Even though we did not specifically investigate late responses, the behaviour seen resembles a two-fold pheromone effect of androstadienone. In ovulating woman, androstadienone would act as a releaser pheromone, as represented by the early peak.
Androstadienone can then operate as a modulator pheromone, as characterised by the late peak . This dual action allows us to speculate on the activation of specific patterns of sexual and reproductive behaviour according to the ovulatory condition, at least in terms of sexual arousal. In contrast, with the non-ovulatory condition, only the modulator effect of androstadienone was preserved, as represented by the late peak. Early activation was also seen here, although, in contrast, it resulted in 11 a temperature decrease, which could represent a negative releaser effect to avoid sexual and reproductive behaviour.
These thermal fluctuations due to androstadienone exposure and their physiological effects across the menstrual cycle are congruent with variations in other autonomic parameters. As already suggested for olfactory perception, around ovulation, women recognize male odour as a pleasant smell, with the tendency thus to make contact with a potential partner. Conversely, in a non-ovulatory period (when there is less chance of pregnancy), the chemosignals that respond to the presence of a male can evoke unpleasant sensations in women (Watanabe et al, 2002) . Moreover, these differences in autonomic responses are not linked to variations in olfactory thresholds.
Pheromone perception appears to be constant across hormone status (Hummel et al, 1991) , while the response to this stimulus is strikingly dependent on hormone status. An evolutionary hypothesis also comes from our thermal data, which is further supported by these results of autonomic responses to non-conscious perception of the male sexual pheromone: the pheromone can elicit specific neuroendocrine activation that regulates sexual and reproductive behaviour.
A new expanding scientific concept is that women have not lost oestrus (Gangestad and Thornhill, 2008) . Our findings support the evidence that when in the fertile periods of their cycles, women are sexually attracted by physiological signals, such as pheromones. Through our ancestral evolution, pheromones were 'designed' for the assessment of predisposed displays of the genetic/ zoological quality of a mate, which we have shown still to be the case here. Thus dual sexuality of women has been hypothesised through the course of human evolution (Gangestad and Thornhill, 2008 ): the oestrus phase, which is related to the female sexual choice for good genes for their offspring, and the non-fertile phase, in which sexual and reproductive behaviour reduce male aggression towards offspring by uncertainties over paternity or as a form of Androstadienone (Steraloids, Inc., Newport, RI) was used in its odourless volatile crystalline form (1 ×10-3 g/vial), to avoid problems linked to solvents and concentrations (Bensafi et al, 2004; Savic et al, 2001 ). The hidden vials that contained either placebo or androstadienone were changed for each woman for each session, with the contents of all of the vials later confirmed by gas chromatography. Subjects rested in comfortable supine position during the experiments, which were performed at the same time of the day in order to avoid possible circadian effects. 13 The data were analysed using paired t-tests within subjects (statistical significance threshold, p <0.05), comparing conditions (ovulatory vs. non-ovulatory) and stimuli (androstadienone vs. placebo) through each experimental phase (adaptation, stimulation and recovery). With the ovulatory women, Lr and N show an early response peak with androstadienone and a delayed peak during recovery, the latter of which is also seen for the non-ovulatory women for Ll, Cl, F and N. 
